Disease-Modifying Therapies (DMTs)

DRUG2 trials

Sponsors

Biogen, SetPoint Medical Corporation

Conditions

Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Unknown Phase

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Active, not recruitingNCT05767736

BiogenMultiple Sclerosis

Start: 2024-06-08End: 2032-12-01Target: 10500Updated: 2025-10-16

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

RecruitingNCT06796504

SetPoint Medical CorporationRelapsing Remitting Multiple Sclerosis

Start: 2026-03-31End: 2030-09-30Target: 60Updated: 2026-04-01